HK1210148A1 - Neurotensin receptor ligands - Google Patents

Neurotensin receptor ligands

Info

Publication number
HK1210148A1
HK1210148A1 HK15110838.8A HK15110838A HK1210148A1 HK 1210148 A1 HK1210148 A1 HK 1210148A1 HK 15110838 A HK15110838 A HK 15110838A HK 1210148 A1 HK1210148 A1 HK 1210148A1
Authority
HK
Hong Kong
Prior art keywords
receptor ligands
neurotensin receptor
neurotensin
ligands
receptor
Prior art date
Application number
HK15110838.8A
Other languages
English (en)
Chinese (zh)
Inventor
Frank Osterkamp
Christiane Smerling
Ulrich Reineke
Christian Haase
Jan Ungewiss
Original Assignee
3B Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3B Pharmaceuticals Gmbh filed Critical 3B Pharmaceuticals Gmbh
Publication of HK1210148A1 publication Critical patent/HK1210148A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK15110838.8A 2012-12-07 2015-11-03 Neurotensin receptor ligands HK1210148A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12008208.6A EP2740726A1 (en) 2012-12-07 2012-12-07 Neurotensin receptor ligands
PCT/EP2013/003700 WO2014086499A1 (en) 2012-12-07 2013-12-06 Neurotensin receptor ligands

Publications (1)

Publication Number Publication Date
HK1210148A1 true HK1210148A1 (en) 2016-04-15

Family

ID=47355771

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15110838.8A HK1210148A1 (en) 2012-12-07 2015-11-03 Neurotensin receptor ligands

Country Status (21)

Country Link
US (2) US10961199B2 (xx)
EP (3) EP2740726A1 (xx)
JP (2) JP6576828B2 (xx)
KR (1) KR102290803B1 (xx)
CN (2) CN104837819B9 (xx)
AU (1) AU2013354422B2 (xx)
BR (1) BR112015012530B1 (xx)
CA (1) CA2893605C (xx)
DK (2) DK3712131T3 (xx)
ES (2) ES2795923T3 (xx)
FI (1) FI3712131T3 (xx)
HK (1) HK1210148A1 (xx)
HU (2) HUE061839T2 (xx)
IL (1) IL239080B (xx)
MX (1) MX370354B (xx)
PL (2) PL3712131T3 (xx)
PT (2) PT2928870T (xx)
RU (1) RU2671970C2 (xx)
SG (2) SG10201704564QA (xx)
WO (1) WO2014086499A1 (xx)
ZA (1) ZA201503446B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10799605B2 (en) 2014-06-10 2020-10-13 3B Pharmaceuticals Gmbh Conjugate comprising a neurotensin receptor ligand and use thereof
EP2954933A1 (en) * 2014-06-10 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand
EP2954934A1 (en) * 2014-06-11 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand and use thereof
BR112018010535A2 (pt) * 2015-11-24 2018-11-13 Transfert Plus Sec compostos peptídicos e conjugados peptídicos para o tratamento de câncer por quimioterapia com mediação por um receptor
EP3279197A1 (en) 2016-08-03 2018-02-07 Friedrich-Alexander-Universität Erlangen-Nürnberg Diagnosis, treatment and prevention of neurotensin receptor-related conditions
WO2018102682A1 (en) 2016-12-01 2018-06-07 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
AU2018219909A1 (en) 2017-02-10 2019-09-12 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-LAG3 antibodies for immuno-PET imaging
CA3070796A1 (en) 2017-07-24 2019-01-31 Regeneron Pharmaceuticals, Inc. Anti-cd8 antibodies and uses thereof
KR20220032079A (ko) * 2019-07-08 2022-03-15 쓰리비 파마슈티컬스 게엠베하 섬유모세포 활성화 단백질 리간드를 포함하는 화합물 및 그의 용도
CN111875667B (zh) * 2020-07-16 2021-12-21 南方科技大学 有机金属螯合物及其制备方法与应用、探针
CA3196365A1 (en) * 2020-10-22 2022-04-28 Tomoyuki Imai Method for producing radioactive zirconium complex
AU2022273867A1 (en) * 2021-05-13 2023-11-23 The General Hospital Corporation Molecular probes for in vivo detection of aldehydes
WO2022261771A1 (en) * 2021-06-16 2022-12-22 Fusion Pharmaceuticals Inc. Combination comprising a neurotensin receptor binding compound, gemcitabine and nab-paclitaxel
WO2022261770A1 (en) * 2021-06-16 2022-12-22 Fusion Pharmaceuticals Inc. Combination comprising a neurotensin receptor binding compound and folfirinox
WO2023141722A1 (en) * 2022-01-28 2023-08-03 Fusion Pharmaceuticals Inc. Ntsr1-targeted radiopharmaceuticals and checkpoint inhibitor combination therapy
WO2023158802A1 (en) * 2022-02-18 2023-08-24 Full-Life Technologies U.S. Inc. Compounds and radioligands for targeting neurotensin receptor and uses thereof
WO2023215778A1 (en) * 2022-05-03 2023-11-09 The University Of North Carolina At Chapel Hill Development of ntsr targeted agents for imaging and therapy applications

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110321A (en) 1976-07-12 1978-08-29 Folkers Karl Synthetic tridecapeptide [Gln4 ]-neurotensin having hormonal activity
US4425269A (en) 1982-06-07 1984-01-10 Merck & Co., Inc. Metabolically protected analogs of neurotensin
US4439359A (en) 1982-07-02 1984-03-27 Merck & Co., Inc. Cyclic octapeptide analogs of neurotensin
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
FR2665898B1 (fr) 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
CA2086453A1 (en) 1992-12-30 1994-07-01 Mcgill University Marker for neurotensin receptor
US5407916A (en) 1993-02-16 1995-04-18 Warner-Lambert Company Neurotensin mimetics as central nervous system agents
FR2711140B1 (fr) * 1993-10-12 1996-01-05 Sanofi Sa 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
WO1995022341A1 (en) 1994-02-18 1995-08-24 Mallinckrodt Medical, Inc. Labelled peptide compounds
US6054557A (en) 1995-04-04 2000-04-25 Advanced Bioconcept (1994) Ltd. Fluorescent peptides
EP0820466A2 (en) 1995-04-04 1998-01-28 Advanced Bioconcept Inc. Fluorescent peptides
FR2732967B1 (fr) * 1995-04-11 1997-07-04 Sanofi Sa 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant
AU6352296A (en) 1995-07-20 1997-02-18 Advanced Bioconcept, Inc. Cell sorting with fluorescent peptides
DE69819478T2 (de) 1997-02-03 2004-09-02 Mallinckrodt, Inc. Verfahren zum Nachweis und zur Lokalisierung maligner menschlicher Pankreastumore
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
EP1067950B1 (en) 1998-04-10 2008-05-14 Mayo Foundation For Medical Education And Research Neo-tryptophan
EP1194444A2 (en) 1999-06-24 2002-04-10 BioSynthema Inc. Labeled neurotensin derivatives with improved resistance to enzymatic degradation
EP2338525A3 (en) * 2003-07-09 2011-08-03 California Pacific Medical Center Remote detection of substance delivery to cells
US20060062729A1 (en) * 2004-09-09 2006-03-23 Carraway Robert E Enhanced ligand binding to neurotensin receptors
WO2008091530A2 (en) * 2007-01-19 2008-07-31 Mallinckrodt Inc. Diagnostic and therapeutic cyclooxygenase-2 binding ligands
EP2100900A1 (en) 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
JP5592377B2 (ja) * 2008-09-16 2014-09-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 放射能標識のための[18f]sfbの単純化ワンポット合成
BRPI0922689A2 (pt) 2008-12-05 2018-11-06 Angiochem Inc. conjugados de neurotensina ou análogos de neurotensina e usos dos mesmos
EP2374003B1 (en) * 2009-01-07 2015-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment, the prognostic assessment and the detection of breast cancer
US9809624B2 (en) 2009-07-16 2017-11-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors
WO2011156557A2 (en) * 2010-06-11 2011-12-15 Thomas James B Compounds active at the neurotensin receptor

Also Published As

Publication number Publication date
PL3712131T3 (pl) 2023-05-02
US10961199B2 (en) 2021-03-30
PL2928870T3 (pl) 2020-09-21
ES2795923T3 (es) 2020-11-25
DK3712131T3 (da) 2023-03-20
SG11201503880YA (en) 2015-06-29
WO2014086499A8 (en) 2014-12-31
JP6576828B2 (ja) 2019-09-18
KR102290803B1 (ko) 2021-08-18
CN104837819B9 (zh) 2019-07-09
MX370354B (es) 2019-12-10
JP7042776B2 (ja) 2022-03-28
DK2928870T3 (da) 2020-07-13
SG10201704564QA (en) 2017-07-28
CA2893605A1 (en) 2014-06-12
US20150299133A1 (en) 2015-10-22
EP2740726A1 (en) 2014-06-11
CN109320502A (zh) 2019-02-12
CA2893605C (en) 2021-08-10
ZA201503446B (en) 2016-01-27
CN104837819B (zh) 2018-12-07
PT2928870T (pt) 2020-05-29
MX2015007193A (es) 2016-03-17
HUE050388T2 (hu) 2020-11-30
KR20150092300A (ko) 2015-08-12
PT3712131T (pt) 2023-04-04
EP2928870B1 (en) 2020-04-08
IL239080B (en) 2019-06-30
WO2014086499A1 (en) 2014-06-12
US20210087149A1 (en) 2021-03-25
AU2013354422B2 (en) 2018-03-15
BR112015012530A2 (pt) 2017-09-12
HUE061839T2 (hu) 2023-08-28
EP3712131B1 (en) 2023-02-01
IL239080A0 (en) 2015-07-30
EP3712131A1 (en) 2020-09-23
EP2928870A1 (en) 2015-10-14
RU2015127086A (ru) 2017-01-11
JP2019218375A (ja) 2019-12-26
AU2013354422A1 (en) 2015-05-28
BR112015012530B1 (pt) 2022-07-19
ES2941629T3 (es) 2023-05-24
FI3712131T3 (fi) 2023-03-28
JP2016501238A (ja) 2016-01-18
CN109320502B (zh) 2022-06-07
CN104837819A (zh) 2015-08-12
RU2671970C2 (ru) 2018-11-08

Similar Documents

Publication Publication Date Title
IL254716B (en) Zinc-lysine conjugate
HK1210148A1 (en) Neurotensin receptor ligands
HK1211039A1 (en) Engineering -cell receptors
DK3327112T3 (en) Agse-deficient stamme
GB201213700D0 (en) Receptor antagnists II
EP2754580A4 (en) DUMP TRUCK
DK2830816T3 (en) Hidtil ukendt coatingkoncept
EP2876220A4 (en) DREDGING
EP2935220A4 (en) PERI-carbinol
EP2920142A4 (en) MÉTHANOFULLERRÈNES
EP2812698A4 (en) TIME RESOLVED FREIGHT AND DOUBLE ACCEPTOR
EP2920157A4 (en) DI MACRO CYCLEN
EP2873363A4 (en) DIOPSIMETER
GB201223053D0 (en) Receptor
GB2500883B (en) Improved saw-horse
EP2834250A4 (de) Lithiumsilikate
ZA201305187B (en) Improved brattice
GB201215542D0 (en) Securing means
GB201220595D0 (en) Keysafe application
GB201221201D0 (en) StickPlec
GB201220309D0 (en) Gapstep
AU345893S (en) Treehouse
GB201207456D0 (en) Swipedot
GB201202303D0 (en) Myhealthbadge
GB201201023D0 (en) Sharkbitze